Skip to content


Adakveo (crizanlizumab) is an antibody pharmaceutical. Crizanlizumab was first approved as Adakveo on 2019-11-15. It has been approved in Europe to treat sickle cell anemia. It is known to target P-selectin.
Trade Name Adakveo
Common Name Crizanlizumab
Indication sickle cell anemia
Drug Class Monoclonal antibodies: humanized, immunomodulating
Get full access now